# Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

> **NCT03386357** · PHASE2 · TERMINATED · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 115 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** A (pembrolizumab+RT)
- **DRUG:** B (pembrolizumab)

## Key facts

- **NCT ID:** NCT03386357
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-20
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-10-01
- **Target enrollment:** 115 (ACTUAL)
- **Why stopped:** slow recruitment
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03386357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03386357, "Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03386357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*